Additive effect of the metabolic syndrome score to the conventional CHADS2 score for the thromboembolic risk stratification of patients with atrial fibrillation

Background The CHA2DS2-VASC scoring scheme may not be better than the CHADS2 scoring scheme in predicting thromboembolic risk for patients with atrial fibrillation (AF) in Asians. Metabolic syndrome is associated with an increased risk of thrombosis. Objective To evaluate whether metabolic syndrome offers incremental information over the CHADS2 scheme in predicting thromboembolic risk for patients with AF in the Taiwanese population. Methods The study population consisted of 721 consecutive patients with AF who had been followed up for a median of 10.8 years. Thromboembolic end points were defined as ischemic stroke/transient ischemic accident and peripheral embolisms. Clinical factors associated with thromboembolic end points were identified by Cox regression analysis. Different scoring systems were compared by receiver operating characteristic (ROC) analysis. Results We found that components in the CHADS2 scheme were associated with an increased risk of thromboembolism. The CHA2DS2-VASC scheme did not provide information additional to that provided by the CHADS2 scheme on thromboembolism risk (ROC area: 0.670 vs 0.665; P > .05). Metabolic syndrome components were also associated with increased risk of thromboembolism. The incident thromboembolic rate increased incrementally when metabolic syndrome score increased. Additional metabolic syndrome components provide additional information to the CHADS2 scheme on thromboembolism risk (ROC area: 0.670 vs 0.729; P = .034). We therefore proposed a new scoring scheme called CHADS2-MS scoring scheme. In patients with low to intermediate CHADS2 scores (0–1), the use of the CHADS2-MS score may additionally identify patients with high-risk AF for future thromboembolism. Conclusions We, for the first time, demonstrated that metabolic syndrome components were associated with thromboembolic risk in Taiwanese patients with AF. In addition to the conventional CHADS2 scheme, the calculation of the CHADS2-MS score provides additional information on stroke risk assessment. The CHA2DS2-VASC scoring scheme may not be better than the CHADS2 scoring scheme in predicting thromboembolic risk for patients with atrial fibrillation (AF) in Asians. Metabolic syndrome is associated with an increased risk of thrombosis. To evaluate whether metabolic syndrome offers incremental information over the CHADS2 scheme in predicting thromboembolic risk for patients with AF in the Taiwanese population. The study population consisted of 721 consecutive patients with AF who had been followed up for a median of 10.8 years. Thromboembolic end points were defined as ischemic stroke/transient ischemic accident and peripheral embolisms. Clinical factors associated with thromboembolic end points were identified by Cox regression analysis. Different scoring systems were compared by receiver operating characteristic (ROC) analysis. We found that components in the CHADS2 scheme were associated with an increased risk of thromboembolism. The CHA2DS2-VASC scheme did not provide information additional to that provided by the CHADS2 scheme on thromboembolism risk (ROC area: 0.670 vs 0.665; P > .05). Metabolic syndrome components were also associated with increased risk of thromboembolism. The incident thromboembolic rate increased incrementally when metabolic syndrome score increased. Additional metabolic syndrome components provide additional information to the CHADS2 scheme on thromboembolism risk (ROC area: 0.670 vs 0.729; P = .034). We therefore proposed a new scoring scheme called CHADS2-MS scoring scheme. In patients with low to intermediate CHADS2 scores (0–1), the use of the CHADS2-MS score may additionally identify patients with high-risk AF for future thromboembolism. We, for the first time, demonstrated that metabolic syndrome components were associated with thromboembolic risk in Taiwanese patients with AF. In addition to the conventional CHADS2 scheme, the calculation of the CHADS2-MS score provides additional information on stroke risk assessment.